← Eichor
Study identifier: NCT06716814 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Condition: Haemophilia A (Moderate or Severe)  ·  Sponsor: Swedish Orphan Biovitrum

PhasePhase 3
Planned participants104
Who can joinMale, 6 Years to no upper limit
Healthy volunteersNo

About this study

This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), PK comparison study (Sobi.BIVV001-003) or SHINE study (Sobi.BIVV001-004). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first). The study starts with the Baseline Visit, which will be done in connection to the end of treatment at the EoT/EoS visit (or equivalent) in the respective parent study. Subsequent study visits (on site or phone call) will be done approximately every 13 weeks until End of Treatment. An End of Study safety phone call will be done 14 (+7) days after the End of Treatment Visit.

This description comes directly from the study's public registry record.

Talk to the study team

Study Physician  ·  +46 (0)8 697 20 00  ·  medical.info@sobi.com

Clinical Program Lead  ·  +46 (0)8 697 20 00  ·  medical.info@sobi.com

Always discuss trial participation with your own doctor first.

Locations (21)

Sobi Investigational SitePlovdiv, BulgariaActive Not Recruiting
Sobi Investigational SiteSofia, BulgariaActive Not Recruiting
Sobi Investigational SiteBrest, FranceActive Not Recruiting
Sobi Investigational SiteBron, FranceActive Not Recruiting
Sobi Investigational SiteLille, FranceActive Not Recruiting
Sobi Investigational SiteStrasbourg, FranceWithdrawn
Sobi Investigational SiteAthens, GreeceActive Not Recruiting
Sobi Investigational SiteCatanzaro, ItalyActive Not Recruiting
Sobi Investigational SiteFlorence, ItalyActive Not Recruiting
Sobi Investigational SiteMilan, ItalyActive Not Recruiting
Sobi Investigational SiteNaples, ItalyRecruiting
Sobi Investigational SiteParma, ItalyActive Not Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06716814